# Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation

Study · id `cardio:ct-nct07739888` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07739888](<https://clinicaltrials.gov/study/NCT07739888>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07739888

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 2500 participants.

## Technical summary

Registry record NCT07739888. Allocation not applicable; no masking; primary purpose treatment. Start 2027-12-30 (anticipated); primary completion 2030-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2500 participants (planned count; ClinicalTrials.gov record NCT07739888, source copy `cardio:ctgov-nct07739888-2026-07-31`, retrieved 2026-10-26)
- Planned start: 2027-12-30 (anticipated) (ClinicalTrials.gov record NCT07739888, source copy `cardio:ctgov-nct07739888-2026-07-31`, retrieved 2026-10-26)
- Primary completion: 2030-12-30 (anticipated) (ClinicalTrials.gov record NCT07739888, source copy `cardio:ctgov-nct07739888-2026-07-31`, retrieved 2026-10-26)
- Completion: 2030-12-30 (anticipated) (ClinicalTrials.gov record NCT07739888, source copy `cardio:ctgov-nct07739888-2026-07-31`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07739888-2026-07-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation
- Acronym: LILAC-TIMI 76
- Condition: Atrial Fibrillation (AF)
- Intervention (Biological): Abelacimab
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: db5cd7d06176f39e3f01b2b73fa5cd6eec1e771f3cc9e69c0c0ad7d9f0b259e0
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
